Qing Lyu is a senior associate at Hogan Lovells Fidelity, Shanghai. She started her professional career in Hogan Lovells in Beijing in 2013. Afterwards, she studied in the LL.M. program of the Georgetown University Law Centre with a focus on antitrust law. In 2017, she re-joined Hogan Lovells Washington D.C. Office where she worked closely with the U.S. antitrust group and international trade group. Currently based in Shanghai, her practice spans across various industries such as high-tech, media and telecom, chemical, shipping and manufacturing. She has advised Chinese and multinational companies in antitrust law matters, including merger control filings, conduct investigations, regulatory compliance and policy analysis.
208
On 29 May 2023, China’s antitrust authority – the State Administration for Market Regulation (“SAMR”) – published the decision against Zizhu Pharma on its webpage. The company was fined by SAMR’s Beijing branch for engaging in resale price maintenance (“RPM”), the antitrust lingo for (...)
211
On 24 March 2023, China’s antitrust authority – the State Administration for Market Regulation (“SAMR”) – issued four regulations implementing the recently amended Anti-Monopoly Law (“AML”), which cover four areas respectively, i.e., monopoly agreements, abuse of dominance, merger review and (...)
18
Yesterday, on 29 August 2022, clearance for the FAW/Refire joint venture transaction was announced on one of the websites of the Chinese antitrust authority – i.e., the State Administration for Market Regulation. That transaction marks the first case where Chinese merger review was handled by (...)
688
On 27 September 2021, just a few days before the week-long National Day break, the State Administration for Market Regulation (SAMR) issued its decision against Bull, a supplier of power connection and extension products from Ningbo in East China. In its decision, SAMR fined Bull for resale (...)
301
On 6 August 2020, the lid was lifted on one of China’s biggest antitrust secrets. On that day, news broke out that a new book authored by the State Administration for Market Regulation ("SAMR") featuring a compilation of antitrust rules had been launched. The compilation contains four (...)
60
On 18 March 2020 the Nanjing Intermediate People’s Court (court) ruled in favor of Yangtze River Pharmaceutical Group and its subsidiary (Yangtze Pharma) in an abuse of dominance case against its suppliers of active pharmaceutical ingredients (API). The court awarded the plaintiffs a record (...)
137
CHINA TABLES FIRST SET OF AMENDMENTS TO THE ANTI-MONOPOLY LAW* On 2 January 2020, China’s antitrust authority – the State Administration for Market Regulation (’SAMR’) – released a draft proposing amendments to the main antitrust statute in China, the Anti-Monopoly Law (’AML’), for public (...)
511
On 1 July 2019, the State Administration for Market Regulation (SAMR) made public three sets of regulations to implement China’s Anti- Monopoly Law (AML) : the Interim Regulation Prohibiting Monopoly Agreements ; the Interim Regulation Prohibiting Conduct Abusing Dominant Market Positions ; (...)
59
NEITHER FISH NOR FOWL – CHINA’S SUPREME COURT PROPOSES NEW FRAMEWORK FOR RESALE PRICE MAINTENANCE* In the last week of June 2019, a copy of a ground-breaking court ruling emerged on social media in China – the order by the Supreme People’s Court (SPC) in the case between Yutai Technology (...)
